23andme

FDA Approves New 23andMe Pharmacogenetic Reports, But There Are Some Caveats

The U.S. Food and Drug Administration (FDA) announced Wednesday that it has approved the marketing of 23andMe’s reports on pharmacogenetics, which the genetic-testing company claims are designed to assess whether genetics may affect an individual’s ability to metabolize certain drugs including antidepressants.